2 weeks Ago By ABMN Staff
Legal & General Group Plc boosted its position in Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM – Free Report ) by 3.5% in the fourth quarter, HoldingsChannel.
com reports. The firm owned 40,820 shares of the company’s stock after purchasing an additional 1,389 shares during the quarter. Legal & General Group Plc’s holdings in Mirum Pharmaceuticals were worth $1,688,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp lifted its holdings in shares of Mirum Pharmaceuticals by 100.0% in the fourth quarter.
Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after buying an additional 357 shares during the period. R Squared Ltd bought a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $69,000. AlphaQuest LLC raised its position in Mirum Pharmaceuticals by 969.
6% in the fourth quarter. AlphaQuest LLC now owns 1,829 shares of the company’s stock worth $76,000 after acquiring an additional 1,658 shares in the last quarter. Avanza Fonder AB acquired a new stake in Mirum Pharmaceuticals in the 4th quarter valued at about $189,000.
Finally, KLP Kapitalforvaltning AS bought a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $277,000. Analyst Ratings Changes Several analysts recently commented on the stock. HC Wainwright increased their target price on shares of Mirum Pharmaceuticals from $66.
00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Robert W.
Baird raised their price objective on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Thursday, February 27th.
Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $58.
20. Insider Buying and Selling at Mirum Pharmaceuticals In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,627 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.
22, for a total value of $126,673.94. Following the transaction, the chief operating officer now owns 26,961 shares in the company, valued at $1,300,059.
42. The trade was a 8.88 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available through the SEC website . Also, CEO Christopher Peetz sold 9,102 shares of the company’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.
22, for a total value of $438,898.44. Following the completion of the transaction, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.
40. The trade was a 7.28 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders have sold a total of 105,557 shares of company stock valued at $4,726,040 in the last 90 days. 22.
87% of the stock is currently owned by corporate insiders. Mirum Pharmaceuticals Trading Up 0.8 % NASDAQ MIRM opened at $40.
80 on Friday. The firm’s 50 day moving average price is $44.12 and its two-hundred day moving average price is $43.
97. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.
15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc.
has a twelve month low of $23.83 and a twelve month high of $54.23.
The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -20.20 and a beta of 1.
00. Mirum Pharmaceuticals ( NASDAQ:MIRM – Get Free Report ) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.
49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.22).
The business had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million.
Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%.
Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.
About Mirum Pharmaceuticals ( Free Report ) Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. Featured Stories Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. ( NASDAQ:MIRM – Free Report ). Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
